Political tension in Poland is rising: opposition MPs staged a protest in parliament against the backdrop of a week-long conflict over the leadership of the Constitutional Tribunal.
As a result of the collision, one car ended up on the roof of another in the city.
The Russian army struck medical infrastructure in Izium with guided aerial bombs. Among the dead are specialists who had been restoring laboratory operations after deoccupation.
Higgsfield co-founder Oleksandr Mashrabov, whose business assets are valued at over $1 billion, has become a citizen of Kazakhstan.
Kateryna Dorozhko-Piven was found guilty of "high treason" and illegal possession of weapons. She was sentenced to 14 years in a correctional colony and one year of restriction of liberty.
Director of the Energy Research Centre noted that damage to high-voltage lines prevents resource transmission to Kyiv and Odesa, leading to its export.
NATO Secretary General Mark Rutte stated that the full restoration of Ukraine's borders is unlikely, and the end of hostilities will involve a peace agreement with elements of compromise.
Within the framework of the "Carthage" criminal case, the court selected a preventive measure for a National Police official, prohibiting the posting of bail.
At first glance, the story of the illegal production of haemostatic bandages "Krovospas" (later rebranded as BloodSaver) and the activities of the major Ukrainian chemical compound producer "Enamine" have nothing in common. However, an analysis of public registers and media materials revealed dense financial and corporate links between these two entities.
In March 2022, at the beginning of the full-scale war, when regulatory inspections were suspended, chemist Igor Tsurupa organised the illegal production of medical devices in the city of Obukhiv in Kyiv Oblast. The "Krovospas" bandages were manufactured in unsanitary conditions, without sterility control, and sold to volunteers under a "goods in exchange for donations" scheme. Major charitable foundations, including the Prytuli Foundation and "Wings of Victory", refused to purchase this product due to the threat to patient health. Also in 2023, an attempt to push one million units of "Krovospas" into Ministry of Defence procurement failed. The National Police opened a criminal case regarding the underground production.
Despite the illegal nature of the activities, the "Enamine" charitable foundation systematically cooperated with Igor Tsurupa, purchasing his products. In fundraising posts from 2023, Tsurupa listed the details of the "BF Enamine" Public Organisation (EDRPOU code 43520050) for donations, alongside his personal accounts at PrivatBank and PayPal. Thus, funds for the illegal production were collected through the accounts of the foundation and the organiser.
Exploiting the absence of control inspections during martial law, the underground production operated at full capacity. On 15 February 2026, Igor Tsurupa stated on his Facebook page that in almost four years, over 3 million packs of bandages and wipes had been produced outside the legal framework, without paying taxes or undergoing quality control.
In February 2026, the organisers announced the closure of the "Krovospas" project and soon presented a new brand — BloodSaver. The manufacturer was Taktyspas LLC, founded by Igor Tsurupa in June 2022. The rebranding was accompanied by the creation of a new website and, according to registers, million-level financial injections.
The key moment was the change of owners of Taktyspas LLC. On 1 July 2025, the Enamine Charitable Foundation and Lyudmyla Babichenko joined the ownership structure. Igor Tsurupa's share decreased from 100% to 51%, while the "Enamine" foundation received 49%. Following this, assets grew from two million to almost twenty-five million within a year.
Lyudmyla Babichenko is the ultimate beneficial owner not only of the foundation but also of Scientific and Production Enterprise "ENAMINE" LLC (NVP Enamine LLC), registered at the address: 78 Winston Churchill Street, Kyiv. The charitable foundation is also registered at the same address. The foundation's director is Andriy Tolmachov, who publicly identifies himself as the CEO and founder of the "Enamine" company.
When information about the investments entered the public domain, representatives of "Enamine" denied that these were their direct investments, citing the fact that the share belongs to the foundation. Legally, the foundation is a separate entity, however, given the shared address, owner and management, such argumentation is perceived as a classic "excuse". The foundation's main activity is providing social assistance, which contradicts owning 49% of a commercial structure that previously operated illegally.
Apart from the "Krovospas" story, the "Enamine" company found itself at the centre of a scandal over the supply of its products to Russian pharmaceutical companies. According to investigation data, prior to the full-scale invasion, "Enamine" employees conducted joint scientific research with Russian colleagues. For example, in 2019, a study funded by a Russian government megagrant was conducted in cooperation with Saint Petersburg State University.
The Latvian entity SIA ENAMINE shipped products to Russian buyers, including the St Petersburg company BIOCAD. One of the batches was sent on 17 February 2022, a week before the invasion. In June 2022, BIOCAD filed a patent application where the base block of the key molecule became a substance from the Enamine catalogue.
After the start of the full-scale war, supply chains became more complex. "Enamine" products continue to reach Russia via India and China. In China, since 2024, the products have been cleared of customs duties and sold by the Shanghai company Genez, a strategic partner of Enamine. On their joint website, import schemes are explained by "geopolitical reasons". After customs clearance in Shanghai, the Ukrainian origin of the molecules legally disappears, allowing them to be supplied to Russia as Chinese reagents. Among Genez's clients is the company Mabwell, which is establishing drug production in Russia.
"Enamine" founded the international marketplace Chemspace in Riga (Latvia), where over 180 suppliers are represented. According to customs data, many of them cooperate with Russia. Specifically:
Despite this, the St Petersburg company BioUnity in 2026 still lists "Enamine" among its suppliers, and Russian-language aggregators index the company as a current source of compounds. "Enamine" employees also continue to speak at international conferences alongside Russian scientists.
Returning to BloodSaver, it is worth noting that the "Enamine" foundation cooperated with Igor Tsurupa even at the stage of illegal production, when other foundations refused such products. Later, through investments by the foundation and Lyudmyla Babichenko, "Krovospas" received a legal shell and financing, which can be qualified as the legitimisation of an underground business.
The international pharmaceutical industry is sensitive to product quality and sanctions risks. The production of haemostatic bandages without quality control and supply chains leading to sanctioned structures create serious reputational threats. The company's partners have the right to ask about the ethics of the owners' behaviour, particularly regarding the legitimisation of artisanal production of medical devices and the supply of chemicals to the aggressor country.
Comments
No comments yet. Be the first!